Announcements Trials
Browse Landscape

Phase

Phase 3 6Phase 1 4Phase NA 2Phase 2 2Phase 1/2 2Phase 4 1

Status

Completed 2

Sponsor Class

OTHER 34NIH 34NETWORK 3INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 1Breast 1

Conditions

Neoplasms 1Lung Neoplasms 1Breast Neoplasms 1

Interventions

Carboplatin 273Paclitaxel 267Gemcitabine 244Bevacizumab 226Cisplatin 218pembrolizumab 214Docetaxel 210Pemetrexed 162Capecitabine 148Fluorouracil 129Oxaliplatin 121Cyclophosphamide 121Nivolumab 112Dexamethasone 100Trastuzumab 89Leucovorin 87Cetuximab 85Rituximab 83Irinotecan 82Injections 81Erlotinib Hydrochloride 70Prednisone 68Doxorubicin 68Temozolomide 67atezolizumab 65Bortezomib 65Ipilimumab 64Fulvestrant 59Radiotherapy 54Drug Therapy 51

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × INDUSTRY × temsirolimus × Clear all
NCT01827267 2018-07-03

Neratinib With and Without Temsirolimus for Patients With HER2 Activating Mutations in Non-Small Cell Lung Cancer

Puma Biotechnology, Inc.

Phase 2 Completed
62 enrolled 12 charts
Thoracic

Lung Neoplasms

NCT00062751 2011-04-15

Study Evaluating Temsirolimus (CCI-779) In Breast Neoplasms

Wyeth is now a wholly owned subsidiary of Pfizer

Phase 2 Completed
108 enrolled 4 charts
Breast

Breast Neoplasms, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡